CoChat

Can the Retinal Screening Interval Be Safely Increased to 2 Years for Type 2 Diabetic Patients Without Retinopathy?

Open access

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: In the U.K., people with diabetes are typically screened for retinopathy annually. However, diabetic retinopathy sometimes has a slow progression rate. We developed a simulation model to predict the likely impact of screening patients with type 2 diabetes, who have not been diagnosed with diabetic retinopathy, every 2 years rather than annually. We aimed to assess whether or not such a policy would increase the proportion of patients who developed retinopathy-mediated vision loss compared with the current policy, along with the potential cost savings that could be achieved. RESEARCH DESIGN AND METHODS: We developed a model that simulates the progression of retinopathy in type 2 diabetic patients, and the screening of these patients, to predict rates of retinopathy-mediated vision loss. We populated the model with data obtained from a National Health Service Foundation Trust. We generated comparative 15-year forecasts to assess the differences between the current and proposed screening policies. RESULTS: The simulation model predicts that implementing a 2-year screening interval for type 2 diabetic patients without evidence of diabetic retinopathy does not increase their risk of vision loss. Furthermore, we predict that this policy could reduce screening costs by ∼25%. CONCLUSIONS: Screening people with type 2 diabetes, who have not yet developed retinopathy, every 2 years, rather than annually, is a safe and cost-effective strategy. Our findings support those of other studies, and we therefore recommend a review of the current National Institute for Health and Clinical Excellence (NICE) guidelines for diabetic retinopathy screening implemented in the U.K.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc11-2282

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Patient-level processes in ReSS model. This flowchart summarizes the process steps that patients in the model follow.
Figure 1 Patient-level processes in ReSS model. This flowchart summarizes the process steps that patients in the model follow.CC BY-NC-ND · PubMed Central
Figure 2 Proportion of type 2 diabetic patients who lost their vision. The figure shows the total proportion of type 2 diabetic patients in the model who lost their vision within the simulated period of 15 years. Results are shown for both the current screening policy (2S) and the proposed three-tier screening policy (3S). Results are averaged over 10 replications of the simulation.
Figure 2 Proportion of type 2 diabetic patients who lost their vision. The figure shows the total proportion of type 2 diabetic patients in the model who lost their vision within the simulated period of 15 years. Results are shown for both the current screening policy (2S) and the proposed three-tier screening policy (3S). Results are averaged over 10 replications of the simulation.CC BY-NC-ND · PubMed Central
Figure 3 Estimated cost of screening over 15 years. The figure compares the estimated total type 2 diabetic patient screening costs over 15 years of the current screening policy (2S) with the proposed three-tier screening policy (3S). Results are averaged over 10 replications of the simulation.
Figure 3 Estimated cost of screening over 15 years. The figure compares the estimated total type 2 diabetic patient screening costs over 15 years of the current screening policy (2S) with the proposed three-tier screening policy (3S). Results are averaged over 10 replications of the simulation.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 49

Metadata

Authors
Chalk, D., Pitt, M., Vaidya, B., & Stein, K.
Affiliations
  • University of Exeter (GB)
  • Royal Devon & Exeter NHS Foundation Trust (GB)
Corresponding author
Chalk, Daniel
Venue
Diabetes Care
Published
2012-07-14
Volume
35
Issue
8
Pages
1663-1668
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2121408450
Cited by
48
References
28
Citations by year
2025: 1 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 6 · 2018: 3 · 2017: 6 · 2016: 2 · 2015: 6 · 2014: 5 · 2013: 5
FWCI
4.79
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by-nc-nd)
  • Open Research Exeter (University of Exeter) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
diabetic retinopathy screening, type 2 diabetes, screening frequency, retinopathy progression, vision loss, cost-effectiveness, computer simulation, NICE guidelines, National Health Service
MeSH terms
Diabetes Mellitus, Type 2, Diabetic Retinopathy, Female, Humans, Male, Mass Screening, Time Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Can the Retinal Screening Interval Be Safely Increased to 2 Years for Type 2 Diabetic Patients Without Retinopathy? https://app.cochat.ai/papers/10.2337/dc11-2282
The paper
Chalk, D., Pitt, M., Vaidya, B., & Stein, K. (2012). Can the Retinal Screening Interval Be Safely Increased to 2 Years for Type 2 Diabetic Patients Without Retinopathy? Diabetes Care. https://doi.org/10.2337/dc11-2282

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.